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ABSTRACT
Super-enhancers are established through the inter-
actions of several enhancers and a large number
of proteins, including transcription factors and co-
regulators; however, the formation of these inter-
actions is poorly understood. By re-analysing pre-
viously published estrogen receptor alpha (ER)
ChIP-seq data sets derived from the MCF-7 cell
line, we observed that in the absence of stimu-
lation, future super-enhancers are represented by
one or a few transcription factor binding event(s)
and these extraordinary enhancers possess a re-
sponse element largely specific to the ER dimer.
Upon hormonal stimulation, these primary binding
sites are surrounded by a large amount of ER and
the critical components of active enhancers, such
as P300 and MED1, and together with neighbouring
sites bound by newly recruited ER , they generate
the functional super-enhancers. To further validate
the role of canonical elements in super-enhancer
formation, we investigated some additional signal-
dependent transcription factors, confirming that cer-
tain, distinguished binding elements have a general
organizer function. These results suggest that cer-
tain signal-specific transcription factors guide super-
enhancer formation upon binding to strong response
elements. These findings may reshape the current
understanding of how these regulatory units assem-
ble, highlighting the involvement of DNA elements
instead of protein–protein interactions.
INTRODUCTION
Estrogen receptor alpha (ER) is a well-studied mem-
ber of the nuclear receptor (NR) superfamily and is a
key hormone-regulated transcription factor (TF) in three-
quarters of breast cancer cases (1). The activation of ER
through 17-estradiol (referred to as estradiol or E2) re-
sults in the translocation of the receptor from the cytoplasm
to the nucleus and strengthens the binding of the recep-
tor and its collaborating factors to regulatory regions of
DNA. These events contribute to the altered, particularly
increased expression of the specific target genes (2). ER
primarily binds the estrogen response element (ERE), ini-
tially described as a conserved regulatory element of the
promoter ofXenopus and chicken vitellogenin genes in 1986
(3). ERE is typically an inverted repeat of the NR half
site (AGGTCA) that is separated by a 3-bp-long spacer
(IR3). There are several variations of this element, which
also binds the ligand-induced ER dimer (4).
The most widely used human cell line to study the behav-
ior of ER is MCF-7. MCF-7 is a well-established in vitro
model for the investigation of estrogen-dependent biologi-
cal processes of breast cancer development, as this model
is an ER+ breast cancer-derived cell line isolated from the
pleural effusion of a patient with metastatic breast cancer
(5,6).
There are several putative ER transcription factor bind-
ing sites (TFBSs) in the reference human genome, but only a
portion of these sites is functionally relevant. Using general
bioinformatic motif scans, more than 1 million of these pu-
tative sites were identified, while the number of optimal or
near-optimal sequence motifs was predicted to be approxi-
mately 230 000 according to previous studies (7,8). Among
these, only a small fraction, 5105 elements, was bound by
ER inMCF-7 cells, while approximately 11 000 additional
ER binding events were identified without the presence of
any ERE in the DNA. The discrepancy between the puta-
tive ER binding sites and those identified in experimental
models may reflect the accessibility of the sites. Chromatin
accessibility has been suggested to drive, in general, the
site selection of TFs and chromatin regions with increased
DNase I hypersensitivity were indeed enriched in cell line-
and tissue-specific TFBSs (9). The emergence of these acces-
sible sites may be primed by cell line-specific factors. More-
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over, priming events at the chromatin level further prepare
the conformational context for subsequent protein–DNA
and protein–protein binding events that ultimately lead to
transcriptional activation.
The major collaborative factors of ER are Forkhead
box protein A1 (FoxA1) and activator protein 2 gamma
(AP2 ) (10,11). FoxA1 plays a role as a pioneer factor, and
it has been proposed that FoxA1 binds∼50% of the regions
occupied by ER, even in the absence of estradiol (12–14).
Moreover, FoxA1 is indispensable for any ER recruitment
(15). AP2 also joins to ER binding sites and may be in-
volved in stabilizing ER-chromatin interactions (10).
Recent studies have suggested that enhancers may form
a higher-order structure within regulatory units, also called
super-enhancers (SEs) (16). Several reports have suggested
that the expression of cell type-specific genes is controlled
through these markedly active enhancer groups. Thus, rel-
evant genes have been published with respect to different
types of cells, with genes defining the nature of a given
cell (17). In cancer cells, SEs are associated with key onco-
genes, such as c-MYC (16,18) and TAL1 (19); therefore, the
genome-wide determination of SE-associated genes would
be useful for mapping additional determinative genes that
may be involved in tumor pathogenesis (20). Thus, an un-
derstanding of how these SEs work would be useful for
bridging the gaps in cell differentiation and tumorigenesis.
Moreover, an understanding of the mechanisms underlying
the manner in which SEs influence the genetic programmes
of a cell could bridge the phenotype–genotype gap as the
foundation for the missing heritability.
According to a current approach of HOMER bioinfor-
matic analysis suite (21), active SEs are defined based on
the elevated local sequence read density of such genomic
regions where the individual ChIP-seq (chromatin immuno-
precipitation followed by high-throughput DNA sequenc-
ing) peaks of the key TFs are closer to each other than 12.5
kb. Each ChIP-seq peak or group of peaks is given a read
density score, sorted based on score values and those that
are located on the region of the graph with a slope >1 are
considered SEs.
Although relevant data have accumulated concerning
how these SEs function, little is known regarding the de-
tailed mechanisms that drive the activities of these com-
plexes. SEs are bound by master regulators (17,22), and
their prediction can also be done based on the simultaneous
presence of BRD4 and/or the active histonemarkH3K27ac
(23,24).
The Mediator complex, which is a key component of
transcription initiation, is involved in the looping of en-
hancers to transcription start sites (25,26). The largestmem-
ber of the Mediator complex, MED1, binds to several nu-
clear receptors, such as thyroid hormone receptor (TR), vi-
taminD receptor (VDR), peroxisome proliferator-activated
receptor gamma (PPAR ), hepatocyte nuclear factor 4 al-
pha (HNF4), ER and glucocorticoid receptor (GR), and
it is also a co-regulator of SEs (17,27). Another subunit of
the complex, MED14, also interacts with GR, HNF4 and
PPAR (27). Previous studies have demonstrated that the
reduced level of Mediator members also affects the expres-
sion of lineage-specific genes, reflecting the absence ofmajor
TFs (28). This effect is consistent with the role of MED1 in
forming a bridge between collaborating promoters and en-
hancers through DNA loop formation (29).
In the present study, using previously published and pub-
licly available ChIP-seq data sets, we conducted a detailed
examination of how ER-driven SEs are formed. We com-
pared the sites with the highest level of ER binding that
upon estradiol treatment, together with the newly activated
regions, were organized into SEs. Unexpectedly, we identi-
fied a subset of the enhancers within SE clusters that plays
distinct roles in the organization of these functional units,
and only these enhancers possess canonical EREs. More-
over, these enhancers have a different profile of protein–
protein interactions upon ligand treatment. Further exam-
ination of the interdependence of ER, FoxA1 and AP2
showed that different TFs have specific subsets of SEs, in
which the cooperative binding events are incidental.
To further validate the role of canonical elements in SE
formation, we investigated several additional NRs and TFs,
confirming the pivotal role of strong binding sites in SE for-
mation.
MATERIALS AND METHODS
Data selection
We investigated seven TFs in five different human and
mouse cell types: ER, FoxA1 and AP2 in the MCF-7
cell line (10,30,31), androgen receptor (AR) in the prostate
cancer-derivedLNCaP cell line (32), JUNB in primary bone
marrow-derived macrophages (BMDM) of the C57BL/6
mouse strain (33), VDR in mouse intestinal epithelial cells
and RAR in the F9 mouse embryonic testis carcinoma cell
line (34). Control and ligand-treated ChIP-seq samples for
the above-mentioned TFs were selected from the publicly
available gene expression omnibus database (35) (Supple-
mentary Table S1).
We selected seven additional E2-treated ER ChIP-seq
samples (8 in total, from which at least 10 000 ER TFBSs
were predicted) for further comparison (Supplementary Ta-
ble S2) (30,36–40). P300, BRD4, MED1 and H3K27ac
ChIP-seq and DNase-seq experiments were also performed
as follows (Supplementary Table S3) (41–43). For strength-
ening our model, several further sets samples of ERChIP-
seq experiments were included in our analysis that cover:
vehicle-treated, untreated samples, vehicle- and E2-treated
FoxA1 knock-down samples, tamoxifen- and fulvestrant-
treated samples as well as a time-course experiment of E2-
treatment (Supplementary Table S3) (8,31,44–47).
Data processing
Raw sequence files of the selected ChIP-seq samples were
downloaded and processed using a previously published
computational pipeline with the hg19 and mm10 refer-
ence genomes (48). ChIP-seq peaks were predicted using
MACS2 (49), and SEs were predicted from the ligand-
treated samples using HOMER findPeaks (21). Artifacts,
based on the blacklisted genomic regions of the Encyclo-
pedia of DNA Elements (50), were removed from the peak
sets using BEDTools (51).
Reads per kilobase per million mapped reads (RPKM)
values for both the control and ligand-treated samples were
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calculated on the summit ±50 bp region of the peaks de-
termined from the corresponding ligand-treated samples.
Peaks with the highest read density (referred to as ‘mother’
peaks) of each future SE were selected from the control
samples. The emerging SE peaks (referred to as ‘daughter’
peaks) were identified in the ligand-treated samples in a sub-
sequent analysis. The detailed information about the sites
of predicted SEs, mother and daughter enhancers was pre-
sented in Additional material (http://dx.doi.org/10.13140/
RG.2.2.22940.49286).
Motif enrichment analysis was carried out by findMotif-
sGenome.pl and was performed on the −50, 50 bp flank-
ing region of the peak summits. The individual and average
read density of the different peak sets was determined by
annotatePeaks.pl (21). Read distribution and average den-
sity heat maps were displayed by Java TreeView (52). His-
tograms and box plots were performed using GraphPad
Prism version 6.00 for Windows (GraphPad Software, La
Jolla, CA, USA, www.graphpad.com).
RESULTS
Putative ER binding sites in MCF-7 cells
To determine the ER cistrome, we collected public ChIP-
seq data sets that included ligand-treated samples with the
highest IP efficiency available. By re-analysing the top eight
estradiol-treated MCF-7 samples derived from six labora-
tories (Supplementary Table S2), we identified a surpris-
ingly large number of ER binding sites (∼189 000 in to-
tal), although the consistency of these sites was rather low;
specifically, in at least two samples, only 56 931 ER TF-
BSs could be predicted (Supplementary Figure S1A and B).
Among these, only 4387 TFBSs were present in all of the
investigated samples, and we named these sites the ‘consen-
sus peak set’ (the consensus ER TFBSs were listed in Ad-
ditional material). The observed heterogeneity may reflect
genetic alterations, the number of cell passages, the estra-
diol concentration used in the specific experiments, the in-
duction time of the estradiol response or other technical
differences, e.g. the number of cells or the protocol used
for ChIP. Measuring DNase I hypersensitivity to identify
chromatin regions accessible for TFs revealed the consen-
sus peak set with the highest chromatin accessibility (Sup-
plementary Figure S1C).
While the majority of the detected ER binding sites are
variegated, ER SEs showed a high degree of consistency
within the reported experiments, highlighting the impor-
tance of these regulatory regions within the genome. No-
tably, more than 90% of the SEs contained at least one peak
from the consensus set (Supplementary Table S2), and, in-
terestingly, these peaks were typically present also in the
vehicle-treated samples (Figure 1A).
Primary enhancers designate future super-enhancers
A comparison of the vehicle- and estradiol-treated sam-
ples (GSM614610 andGSM614611 ERChIP-seq samples
were used during the main analysis) revealed that in the ab-
sence of ligand, each SE was represented by one or a few
peak(s) and ligand-induced SEs formed around these acti-
vated genomic regions. In the selected sample, 392 highly
covered regulatory regions could be predicted by the SE
finder of HOMER (Supplementary Figure S1D).
Figure 1A concentrates on the new binding events but
cannot emphasize the increase on pre-occupied regions; the
exact coverage of the examples is shown on Supplementary
Figure S1E. Notably, these individual peaks could not be
predicted as SEs in the vehicle-treated samples, as the cur-
rently used prediction criteria rely mainly on the presence
of clusters of enhancers. These peaks are individual or a
few separate peaks, but upon ER activation, a cluster of
peaks assembles and is clearly identified as SEs. Based on
this observation, we considered that these preferential pri-
mary enhancers may play a key role in the formation of SEs,
such as regulatory units; therefore, we further investigated
these genomic regions.
We examined the size distribution of ER peaks (4042
peaks were investigated), plotting eachmember of ER SEs
based on their tag density (in deciles) (Figure 1B and C).
As a control, we used other ER TFBSs that do not cluster
in SEs (75 693 peaks) (Figure 1D and E). The top 10% of
SE peaks had an extremely high tag density compared with
the other sites in both vehicle- and estradiol-treated samples
(Figure 1B andC). Although the distribution of the tag den-
sity was similar under both conditions, a more than 5-fold
increase in themedian tag density was observed upon ligand
treatment. To exclude technical issues as the cause of this
observation, we performed the same analysis using another
set of ERChIP-seq samples and observed the same results
(Supplementary Figure S1F and G). Plotting the ER en-
richment of all ER-bound single enhancers that are not
members of a SE revealed one-tenth of the tag density of
these sites compared with the peaks within SEs. These re-
sults suggest that the binding events outside of SEs are less
pronounced (Figure 1D and E).
According to the assumption that primary enhancers
form the basis of SEs, we referred to these elements as
‘mother enhancers’, and the subsequently appearing sec-
ondary enhancers were referred to as ‘daughter enhancers’.
The determination of mother and daughter enhancers is de-
scribed in the data processing description in the Materials
and Methods section.
To globally determine whether the binding of ER to the
so-called mother enhancers precedes binding to the sub-
sequent so-called daughter enhancers within the SEs, we
sorted all ER SEs based on the RPKM values of the
mother enhancers (calculated from the vehicle-treated sam-
ples). In Figure 1F, mother enhancers were well separated,
and a relatively low coverage of the daughter enhancers was
observed. However, upon ligand treatment, the existence of
enhancers was detected on the majority of ER SEs (Fig-
ure 1F and G, Supplementary Figure S2A and B). We also
plotted the average tag density of the ER SE peaks, indi-
cating that mother enhancers show even higher signals in
the vehicle-treated samples than daughter enhancers upon
estradiol treatment (Figure 1H and I, Supplementary Fig-
ure S3A and B).
To validate the precedence of mother enhancer occu-
pancy, we compared vehicle-treated and untreated ER
ChIP-seq samples (Supplementary Figure S4A). These data
suggest that vehicle treatment of MCF-7 cells changing the
ER binding neither on mother nor on daughter enhancer
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Figure 1. MCF-7-specific estrogen receptor alpha (ER) super-enhancers are represented by one (or a few) enhancer(s) even in the absence of estradiol
treatment. (A) Integrative Genomics Viewer (IGV) snapshot of ER ChIP-seq coverage representing six ER super-enhancers (SEs) upon vehicle and
estradiol (E2) treatment. The interval scale is 50 in both cases. (B and C) ER tag density upon vehicle or E2 treatment in the deciles determined based
on ER recruitment at peaks within SEs. (D and E) ER tag density upon vehicle or E2 treatment in deciles determined based on ER recruitment at
peaks not overlapping with SEs. The boxes represent the first and third quartiles, the horizontal lines indicate the median reads per kilobase per million
mapped reads (RPKM) values, and the whiskers indicate the lower and upper extremes per decile. (F and G) ER tag densities of the mother (M) and the
top 6 daughter enhancers (1–6) within the same super-enhancer region in vehicle- and E2-treated MCF-7 cells. Enhancers were vertically sorted based on
the RPKM values of the mother enhancers (in the first column), and the individual enhancers within a SE region were subsequently horizontally aligned
based on the read enrichment of the vehicle-treated samples. (H and I) Histograms show the average tag density of mother (392) and daughter enhancers
(3650) in the presence or absence of E2. (J and K) Histograms show the average tag density of mother (392) and daughter enhancers (3650) in the presence
vehicle- or E2-treatment and upon tamoxifen- and fulvestrant-treatment. Samples derived from the same experiment.
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regions. The processed time-course experiment also sug-
gested that mother enhancers are indeed occupied prior to
daughter enhancers, and show a prolonged binding at later
time points, too (Supplementary Figure S4B–D). Thus,
there is a difference between the dynamics of the occupancy
of the distinct SE peak sets. Importantly, the presence of
ER on mother enhancers is remarkable after ER antag-
onist treatments such as tamoxifen and fulvestrant (Figure
1J and K). Moreover, in FoxA1-depleted state, as shown on
Supplementary Figure S4E–G, the binding of ER is re-
duced, but not abolished neither on mother nor on daugh-
ter enhancers.
As MED1 was reported to be a key component of the
Mediator complex bridging SEs with transcription start
sites, we visualized the presence of this component within
the ER SEs. MED1 is recruited to ER-bound sites with
a high binding affinity to the buds or initiator(s) of SEs,
namely, mother enhancers, upon estradiol treatment (Fig-
ure 2A). We also investigated the MED1 densities based on
the previously defined and sorted deciles of ER peaks, and
as shown in Figure 2B and C, Mediator is preferentially re-
cruited to ER peaks with higher tag densities, particularly
in estradiol-treated samples (Figure 2C). Collectively, we
observed collaborating enhancers clustered in SEs, showing
a much higher ER occupancy than single enhancers, and
even more prominent enrichments accompanied by Media-
tor binding were observed within SEs.
The read distribution plot around the individual en-
hancers demonstrated that mother enhancers are located
in the most accessible chromatin regions with high lev-
els of DNase I signal and show the highest MED1, P300,
H3K27ac and BRD4 coverage upon induction, suggesting
that the top ER enhancers (392 mother enhancers in to-
tal) represent the most active regulatory regions, while the
daughter enhancers (3650 in total) did not show this pattern
(Figure 2D, Supplementary Table S3).
Based on the previous observation, namely, that each
super-enhancer region is indicated by a markedly active re-
gion, we assessed whether mother and daughter enhancers
were observed for other TFs and cell types. First, we exam-
ined the other two lineage-determining factors associated
with MCF-7 cells, namely, FoxA1 and AP2 (Supplemen-
tary Figure S2C–F). Second, we extended these investiga-
tions to other NRs in different cell types (AR in LNCaP
cells, RAR in mouse F9 cells and VDR in mouse intesti-
nal epithelial cells) and to JUNB in mouse BMDMs (Sup-
plementary Figure S2G–N). In all experimental systems
investigated (except for FoxA1, as described later in this
manuscript), patterns similar to those for ER in MCF-
7 cells were observed, indicating that a more general phe-
nomenon occurs in the presence of several TFs (Supplemen-
tary Figure S2A–N, Figure S3A–N).
Canonical elements drive transcription factors
To better understand the factors that discriminate ER
mother and daughter enhancers, we applied a motif enrich-
ment analysis for these regions. While mother enhancers
showed strong canonical EREmotif enrichment from a rel-
atively low number of target sequences, daughter enhancers
were not enriched for the ER dimer-specific elements but
were enriched for NR half sites and FoxA1 motifs (Fig-
ure 3A and B and Supplementary Figure S5A and B). In-
terestingly, at the sites of mother enhancers, a unique NR
direct repeat element with overlapping half sites was also
identified. Considering the strong P-value (1e-200) and the
high enrichment of ERE (62.2%) (compared with the back-
ground, which was 3.37%), despite the small number of tar-
get sequences (n = 328), we concluded that the high level of
ER recruitment at mother enhancers (even in the absence
of estradiol) reflects strong canonical DNA elements. How-
ever, for the emergence of daughter peaks, other TFs, such
as FoxA1 and activator protein 1 (AP-1), act in concert with
the increased level of ER after estradiol treatment.
To validate these observations, we examined themotif de-
pendence of binding frequency. We plotted the motif scores
of the remapped EREs as a function of the deciles derived
from the vehicle-treated peak size distribution in the case of
mother enhancers and from the estradiol-treated peak size
distribution in the case of daughter enhancers and observed
that in all cases, the extremely high mother peaks had sig-
nificantly stronger binding elements than the daughter en-
hancers (deciles 8–10 have P < 0.0001) (Figure 3C). This
finding suggests that the strongest elements of accessible eu-
chromatic regions irresistibly attract the ER dimers. To de-
termine whether this effect is also observed for the binding
of other TFs, we investigated these correlations for other
types of SEs.
Motif enrichment analysis at the sites of the mother
and daughter enhancers predicted from other investigated
samples showed the same phenomenon. For example, we
detected better motif enrichment of mother enhancers in
MCF-7 for FoxA1 than that of their daughters, and this
effect was also observed for AP2 (Supplementary Fig-
ure S5C–F). Interestingly, AP2 daughter enhancers har-
boured the motifs of the main collaborating partners,
FoxA1, ER and AP-1, together with the CCCTC-binding
factor (CTCF). In the case of AR in the LNCaP cell line,
FoxA1 is needed for the establishment of mother enhancers,
as shown by the extremely high motif enrichment in the
mother enhancers (Supplementary Figure S5G and H).
Importantly, daughter enhancers showed lower IR3/ARE
(ARE: androgen response element) and FoxA1 motif en-
richment, but a composite element of FoxA1 and AR was
also identified, indicating a tight collaboration between
these TFs, which may be less affected by other regulators.
In the case of JUNB, mother enhancers of mouse
BMDM cells showed all the main specific motif enrich-
ments, namely, AP-1, AP-1::IRF (IRF: interferon reg-
ulatory factor) composite element (AICE), cAMP re-
sponse element and the motif of the lineage-determining
CCAAT/enhancer-binding protein (C/EBP). These motifs
showed weaker enrichment in daughter enhancers, and fur-
ther motifs of collaborating TFs, namely, purine-rich box-1
(PU.1), nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-B) and signal transducer and activator
of transcription (STAT) appeared (Supplementary Figure
S5I and J). TheRAR andVDRmother enhancers of mouse
F9 and epithelial cells, respectively, also showed stronger
specific motif enrichment than the corresponding daughter
peaks, and GATA protein(s) may also occupy VDRmother
enhancers. However, daughter enhancers also showed pu-
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Figure 2. MED1 is recruited to ER-bound sites with an extremely high binding affinity. (A) IGV snapshot of MED1 and ER ChIP-seq coverage,
representing six ER SEs upon vehicle and estradiol (E2) treatment. The interval scale is 50 in both cases. (B and C) MED1 tag density upon vehicle or E2
treatment in deciles determined based on ER recruitment at peaks within SEs. The boxes represent the first and third quartiles, horizontal lines indicate
the median RPKM values, and whiskers indicate the lower and upper extremes per decile. Paired t-test, * significant at P < 0.05; ** at P < 0.01; *** at P
< 0.001; **** at P < 0.0001. (D) Read distribution plot of ER, DNase I, MED1, P300, H3K27ac and BRD4 upon vehicle or E2 treatment, relative to
SE peaks in 2-kb frames. Mother (392 in total) and daughter (3650 in total) peaks are sorted according to ER tag density.
tative AP-1 and Kru¨ppel-like factor (KLF) binding sites
(Supplementary Figure S5K–N).
All examined TFs playing roles in SE formation showed
a phenomenon similar to that of ER, namely, these pri-
mary regulatory regions possessed canonical elements spe-
cific to dominant TF(s), while the further occupied regions
had fewer specific elements together with their collabora-
tive factors. The binding of canonical elements precedes,
and upon treatment, likely facilitates the occupation of the
nearby regions by dominant TFs and interacting partners.
In summary, the primary ChIP-seq peaks, which were
present prior to estradiol stimulation, had significantly
stronger binding elements than the activated peaks, sug-
gesting that certain elements have high DNA–protein inter-
action affinities and that there is no need for cooperative
binding with other factors, e.g. FoxA1 or AP2 . Therefore,
we examined the differentially enriched ER and FoxA1
binding on ER SEs. As shown in Figure 3D and E, the
occurrence of ER on the mother enhancers within ER
SEs is a predominant event (P < 0.0001), but interestingly,
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Figure 3. Canonical elements provide higher DNA-binding affinity than non-canonical elements. (A and B) Motif enrichments of mother and daughter
enhancers. The P-value and target and background (Bg) percentages are included for each motif. (C) Estrogen response element (ERE) motif scores in the
deciles determined based on ER recruitment upon vehicle (in the case of mother enhancers) or E2 treatment (in the case of daughter enhancers) within
SEs. (D and E) RPKM values of ER and FoxA1 coverage at ERmother and daughter enhancers. In the case of panels C, D and E, the boxes represent
the first and third quartiles, the horizontal lines indicate the median RPKM values, and the whiskers indicate the 10th to 90th percentile ranges per decile.
Paired t-test, * significant at P < 0.05, ** at P < 0.01, *** at P < 0.001, **** at P < 0.0001.
FoxA1 also shows a similar pattern (P < 0.0001). The re-
sults suggested that the binding affinity of ER was defi-
nitely higher at the sites of mother enhancers, and FoxA1
showed a stronger binding at these sites despite the lack
of its binding elements that might mean the importance of
protein–protein interactions, namely the binding to ER.
ER , FoxA1 and AP2 form distinct SEs
Previous studies have suggested that interactions with col-
laborating pioneer factors are necessary for ER function;
therefore, we conducted a detailed investigation of how
ER, FoxA1 and AP2 recruitment correlates with each
other at the SE regions and examined the extent of the
overlap between the SEs of these MCF-7-specific TFs. For
this purpose, we plotted the FoxA1 and AP2 tag den-
sity of mother and daughter ER enhancers (Figure 4A),
and the resulting read distribution heat map showed a pos-
itive correlation between the three TFs following estradiol
treatment, but the recruitment of the collaborating TFs was
much lower than that of ER. Examining the mother and
daughter FoxA1 peaks revealed an increase in AP2 bind-
ing but not in FoxA1 and ER binding (Figure 4B), and we
consistently obtained a similar result for AP2 SE peaks
(Figure 4C). Measuring the tag density of the three TFs on
their SEs showed that ER is typically much less frequently
recruited at the mother (and daughter) peaks of the other
two TFs (Figure 4D and E) compared with the recruitment
of FoxA1 and AP2 at the sites of ER SEs. This effect was
also observed for the recruitment of FoxA1 and AP2 at
each other’s SEs (Figure 4F–I), suggesting that SEs are typ-
ically dominated by a single TF and that other TFs are likely
collaborating partners in their activity. TF specificity was
also confirmed by the overlap of SEs determined for ER,
FoxA1 andAP2 (Figure 4J). TheVenn diagram shows that
of these three proteins, ER and FoxA1 have a more dis-
tinct SE profile, while AP2 has its own, less prominent,
SE profile. This finding is consistent with the coverage re-
sults shown in Figure 4A–C, asAP2 was induced at all SEs
examined. The observed dominances may reflect the canon-
ical elements because not only the ER-bound mother en-
hancers but also those of FoxA1 andAP2 showed stronger
specific motif enrichment compared with that in the cor-
responding secondary regions (Figure 4A and B, Supple-
mentary Figure S5A–F). On FoxA1- and AP2 -driven SEs
FoxA1 showed no notable change upon E2 treatment, but
interestingly, it did show higher density on ER-dominated
SEs (Figure 4A–C). The former is not surprising as no sig-
nificant change could previously been observed in FoxA1
binding upon E2 stimulation (46), but the latter is striking
as we found a set of genomic regions, where E2 could affect
FoxA1 binding.
Focusing on some ER-driven SEs, we observed that
there is typically at least one FoxA1-bound enhancer per SE
in the absence of estradiol; however, these enhancers rather
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Figure 4. ER, FoxA1 and AP2 form distinct super-enhancers. (A–C) Read distribution plot of ER, FoxA1 and AP2 upon vehicle or E2 treatment,
relative to each other’s SE peaks in 2-kb frames. The number of mother and daughter peaks, sorted based on tag density, is indicated. (D–I) ER, FoxA1
and AP2 tag density of each other’s mother and daughter enhancers in E2-treated MCF-7 cells. (J) Area-proportional Venn diagram illustrates the
overlaps between the ER, FoxA1 and AP2 SEs.
occasionally overlap with mother enhancers (Figure 5 and
Supplementary Figure S6A and B). In contrast, AP2 did
not show enrichment prior to treatment and emerged to-
gether with ER, typically at mother enhancers and specific
daughter enhancers occupied by FoxA1 (Figure 5 and Sup-
plementary Figure S6C and D). There is a similar enrich-
ment at ERmother enhancers as of AP2 , which suggests
an ERE/ER-dependent FoxA1 and AP2 recruitment by
protein–protein interactions. Importantly,MED1 is specific
only to mother enhancers, while P300 may also be recruited
to regions bound by FoxA1. H3K27ac and BRD4, together
with the DNA accessibility, also followed these tendencies,
thus showing elevated activity upon treatment (Figures 5,
6A, D, G, J, M).
By examining the presence of DNase I, MED1, P300,
H3K27ac, BRD4 and collaborating TFs on FoxA1- and
AP2 -driven SEs, we observed a striking phenomenon: as
ER recruitment is neither induced at these sites, P300,
H3K27ac and BRD4 nor show enrichment, while DNase I
signal and MED1 binding is induced upon treatment (Fig-
ure 6B and C, E and F, H and I, K and L, N and O, Sup-
plementary Figure S7A and B). Notably, according to the
enrichment of H3K27ac and BRD4, the slight decrease in
P300 recruitment did not affect these regions, as they were
already at least as active in the untreated state as the in-
duced ER SEs, and this activation did not change (Fig-
ure 6G–I). These results strongly suggest ER-dependent
MED1/P300 recruitment, followed by histone acetylation
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Figure 5. Recruitment of FoxA1 and AP2 at ER super-enhancers. IGV snapshot of ER ChIP-seq coverage, representing eight ER SEs upon vehicle
(veh) or E2 treatment and the simultaneous presence of FoxA1, AP2 , MED1, P300, H3K27ac, BRD4 and DNase I upon vehicle and E2 treatment. The
interval scales are indicated in the upper left corners. Peaks, highlighted in grey, represent the sites of ER mother enhancers, while dashed lines indicate
the location of FoxA1 peaks.
and BRD4 binding (Figure 6A,D,G, J,M), while at FoxA1-
and AP2 -dominated SEs, only MED1 recruitment and el-
evated chromatin accessibility were observed upon estra-
diol treatment (Figure 6E and F). On FoxA1- and AP2 -
dominated SEs estradiol treatment results in MED1 bind-
ing. However, because P300 is not further recruited, neither
histone acetylation nor the readingmodule of the acetylated
histones, namely BRD4 will be further recruited to these
sites (Figure 6E, F, H, I, K, L, N, O and Supplementary
Figure S7A and B). These events suggested that in the case
of TF-specific SE recruitment and the increase in MED1
binding, an increase in DNase I hypersensitivity is not suf-
ficient for the initiation of these events. However, it is impor-
tant to note that AP2 -dominated SEs showed themost en-
riched active enhancer marks (Figure 6C, F, I, L, O), while
those of FoxA1 were the least active (Figure 6B, E, H, K,
N).Moreover, ER bound in a scatteredmanner to FoxA1-
and AP2 -specific SEs (Supplementary Figure S6E–L).
DISCUSSION
In this study we first describe ligand-inducible super-
enhancers. Due to the almost prompt biological response
(Supplementary Figure S4A–D) and the large variety of
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Figure 6. FoxA1 and AP2 mother enhancers are located in active regions but are not inducible compared with ER mother enhancers. The box plots
demonstrate the accessibility of DNase I and the recruitment of MED1, P300, H3K27ac and BRD4 within the (A,D,G, J andM) ERmother enhancers,
(B, E, H, K, N) FoxA1 mother enhancers and (C, F, I, L and O) AP2 mother enhancers. The boxes represent the first and third quartiles, the horizontal
lines indicate the median RPKM values and the whiskers indicate the 10th to 90th percentile ranges per decile. Paired t-test, * significant at P < 0.05, **
at P < 0.01, *** at P < 0.001, **** at P < 0.0001.
available (NGS) data (Supplementary Tables S1–S3), acti-
vation of ER in MCF-7 is an appropriate system to model
the formation of SEs, and our basic findings might be true
for the establishment of any cluster of enhancers in any cell
type.Using several cell typeswe tested further inducible TFs
(Supplementary Table S1) and found that typically there is
one (or a few) high-affinity response element (Figure 3A–
C, Supplementary Figure S5) that forms the core of the
developing SEs (Figures 1A, F and G and 2A). Inducible
SEs possess the same phenomena as previously described
for ‘steady-state’ SEs, the enrichment forMediator proteins,
co-regulators and active histone marks (17) (Figures 2D
and 6), however, the large extent of protein–protein inter-
actions between TFs was not as pronounced as previously
described. In contrast, the examined SEs are driven rather
by one single TF (Figure 4), which then recruited the further
proteins (Figure 7).
The fact that enhancers cooperate with each other from
even more than a 10-kb distance suggests the establishment
of a similar system between promoters and enhancers, and
this effect cannot be explained without loop formation. The
Mediator complex promotes these looping events and was
indeed associated with SEs (17,28). Nevertheless, the pre-
cise structure of these finger-like formations and the man-
ner in which these complexes are held together remain un-
known. Another feature of these outstandingly active, open
chromatin regions is the presence of P300 that acetylates hi-
stone lysine residues (53). In addition to P300, which not
only establishes but also binds acetylated histones, another
bromodomain-containing protein, BRD4, is also enriched
in these genomic regions (54), together providing accessi-
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Figure 7. Working model of an ER-dominated SE in the presence or absence of estradiol. The upper, closed chromatin region demonstrates the presence
of EREs within a SE, and one of these regions provides a canonical DNA-binding element (red box) for mother enhancers in the absence of treatment.
Upon E2 treatment, the resulting SE region becomes more opened and E2 treatment recruits several ER molecules, which may occupy the surrounding
non-canonical EREs. The existence of a canonical element provides competition between ERs, and the attracted ERs likely bind to neighbouring non-
canonical EREs rather than to similar non-canonical EREs in the distal regions of the genome. The SE region becomes more acetylated and MED1 and
P300 bind to ER that subsequently binds a canonical ERE.
bility of the regulatory sites for TFs. The previously exam-
ined steady-state SEs are occupied by lineage-determining
factors (e.g. PU.1, MyoD, C/EBP), which are cell type-
specific, highly expressed proteins (17). In addition to these
key regulators, the results of the present study suggest that
ligand-inducible TFs (NRs) also play a prominent role in
the establishment of SEs. Although we have proof about
several DNA–protein and protein–protein interactions in
SEs, it is difficult to model how these complexes form and
subsequently regulate gene expression.
Another regulatory unit, called the ‘hot spot’, where
protein–protein interactions lead to the presence of several
TFs at a single locus, has been described (55). Integration
of the two functional units, SE and the regulatory hotspot,
has revealed at least one TF-dense area in each SE re-
gion (56). This finding suggests that during adipocyte repro-
gramming, the high number of TFs, including C/EBP, AP-
1, NRs and several other regulators, attracts more MED1.
In the case of ER-driven SEs in MCF-7 cells, we ob-
served a similar phenomenon (Figures 2, 5, 6D); however,
these regions beside their FoxA1-dependence (Supplemen-
tary Figure S4E–G) showed strong ERE-, estradiol- and
ER-dependence (Figure 3) and did not show the definitive
necessity of interactions between a large number of different
kinds of TFs (Figure 4D–I).
We referred to ER-dense ‘hot spots’ as mother en-
hancers because these elements were detected prior to stim-
ulation, and additional regulatory regions were referred to
as daughter enhancers.Mother enhancer is special from sev-
eral points of view: (i) it has typically a strong binding el-
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ement specific for one single TF (Figure 3A); (ii) the pre-
dominant TF is able to recruit several other proteins such
as AP2 , FoxA1 and further co-regulators (Figures 2D and
4A); and (iii) it is located in a highly accessible regula-
tory region (Supplementary Figure S1C), which probably
makes possible the accessibility of neighbouring regulatory
regions (Figure 7). Unlike mother enhancers, TF recruit-
ment at daughter enhancers is much less dynamic (Supple-
mentary Figure S4D). These regions are similar to any fur-
ther enhancers. They might be discriminated from typical
enhancers by the proximity to mother enhancers (Figure
1A) or their higher ER occupancy (Figure 1B–E).
Examination of themainTFs that collaboratedwithER
revealed that although AP2 was recruited at mother en-
hancers and permanent FoxA1-bound daughter sites upon
treatment (Figure 5 and Supplementary Figure S6A–D),
this recruitment appears consequential due to the presence
of preoccupied mother enhancers. We had a unique obser-
vation that FoxA1 binding increased mostly at mother en-
hancers upon E2 treatment (Figure 4A), which, in the lack
of the enrichment of its binding element, is probably due
to the interaction with ER and AP2 . Importantly, only
these sites showed increased P300 recruitment (Figure 5),
and the enrichment of H3K27ac and BRD4 was also ob-
served (Figures 5 and 6J and M).
SEs are typically formed from several enhancers. The re-
sults of the present study revealed that a large fraction of
these individual ER enhancers did not show significant
FoxA1, AP2 or P300 binding, rather, enhanced histone
acetylation-dependent BRD4 enrichment (Figures 2D and
5). There are two explanations for how these elements are
bound by ER: (i) less common TFs without enriched mo-
tifs recruit ER via protein-protein interactions or (ii) non-
canonical EREs can also be occupied by an elevated num-
ber of ERmolecules. The formermechanismmay also play
a role similar to those of FoxA1 and AP2 , but the latter
mechanism seems to be more significant in this system.
It is well known that FoxA1 is required for and AP2
facilitates ER binding (10,11). However, we suggest that
ER binding is differently regulated in SEs. Our compre-
hensive analyses revealed that high-affinity binding sites at-
tract ER, even in the absence of ligand or FoxA1, however,
there is no ER-specific SE formation without this pro-
tein. In FoxA1 expressing cells estradiol treatment recruits
additional ER proteins, which occupy surrounding non-
canonical EREs (Figure 7). Preformed or forming finger-
like small loops facilitate the concentration of enhancers
in a milieu with high ER density that contains complexes
generated from the direct and indirect interaction partners
of ER. The basic phenomenon, i.e. the presence of mother
enhancers with canonical elements, governed via different
signal-dependent transcription factors, was also observed
in additional cellular systems, suggesting that this type of
regulation generally occurs inmammalian cells.We propose
that these findings may change the current view of how SEs
are generated and regulated.
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